Abstract:Yawan Jing, 1, 2 Ruixin Cheng, 3 Hao Zeng, 1 Qin Huang, 1 Dongyu He, 1 Jiayi Sun, 1 Panwen Tian, 1, 4 Yalun Li 1, 4 1 Department of Pulmonary and Critical Care Medicine, State Key Laboratory of Respiratory Health and Multimorbidity, Institute of Respiratory Health and Multimorbidity, Institute of Respiratory Health, Frontiers Science Center for Disease-Related Molecular Network, Precision Medicine Center/Precision Medicine Key Laboratory of Sichuan Province, West China Hospital, Sichuan University, Chengdu, Sichuan, People's Republic of China; 2 Department of Gerontology and Geriatrics, Tibet Autonomous Region People's Hospital, Lhasa, Tibet Autonomous Region, People's Republic of China; 3 Department of Radiation Oncology, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, Guangdong, 510080, People's Republic of China; 4 Lung Cancer Center/Lung Cancer Institute, West China Hospital, Sichuan University, Chengdu, Sichuan, People's Republic of China Correspondence: Yalun Li; Panwen Tian, Department of Pulmonary and Critical Care Medicine, West China Hospital, Sichuan University, No. 37 GuoXue Alley, Chengdu, Sichuan Province, 610041, People's Republic of China, Tel/Fax +86 28 85423660, Email ; Background: KRAS mutation is one of the most common driver oncogenes in non-small cell lung cancer (NSCLC), and the most common mutation subtype is G12C . However, there is still a lack of efficacy and prognosis data related to immunotherapy, which hinders the promotion of new strategies. Methods: Clinical characteristics and treatment outcomes were collected and analyzed for patients with NSCLC harboring KRAS mutations at West China Hospital of Sichuan University from June 2013 to March 2023. Results: Among the 231 patients with KRAS -mutated NSCLC, 29.4% had KRAS G12C mutations. Compared to the KRAS non-G12C NSCLC group, the KRAS G12C NSCLC group had a greater number of pack-years. The programmed death ligand 1 expression and the proportion of patients with a high tumor mutational burden were not significantly different between the two groups. Similar patterns of TP53, STK11 , and CDKN2A mutations were observed between KRAS G12C and KRAS non-G12C NSCLC groups. The median progression-free survival (PFS) (8.4 vs 7.0 months, p=0.100) and overall survival (OS) (12.1 vs 18.1 months, p=0.590) were not statistically different between KRAS G12C and KRAS non-G12C . Compared to patients with KRAS G12C NSCLC who did not receive immunotherapy, patients who received immunotherapy had a better objective response rate (46.2% vs 0%, p=0.002), PFS (12.2 vs 7.5 months, p=0.087) and OS (49.9 vs 11.1 months, p=0.12). Conclusion: Patients with KRAS G12C were more likely to be smokers. Advanced KRAS G12C NSCLC patients who received immunotherapy had a better ORR than those who did not, suggesting that patients with G12C mutations are more likely to benefit from immunotherapy. Keywords: non-small cell lung cancer, KRAS G12C mutation, KRAS mutation, immunotherapy, overall survival Lung cancer is the leading cause of cancer-related mortality, accounting for more than 1.8 million deaths a year, and non-small cell lung cancer (NSCLC) is the most common subtype. 1–3 KRAS mutations are present in 25–39% of non-squamous NSCLCs. 4–6 The KRAS G12C mutation is present in approximately 40–46% of patients with KRAS -mutant NSCLC and 13–16% of those with lung adenocarcinoma 6 and is the most common KRAS mutation in lung cancer. 7,8 KRAS G12C inhibitors represent a significant advancement in the field of targeted therapies for NSCLC. 9–18 According to the latest version of the National Comprehensive Cancer Network (NCCN) clinical practice guidelines, the optimal first-line therapy for advanced KRAS -mutant NSCLC still consists of programmed cell death (ligand) 1 blockade alone or in combination with platinum-based chemotherapy, 19 and resistance to KRAS inhibitor monotherapy will eventually develop. 6,20,21 Given that drug combination therapy is currently a clinically recognized strategy for overcoming resistance to KRAS G12C inhibitors, combining KRAS G12C -targeted drugs with other drugs (such as immunotherapy and chemotherapy) may be one of the key strategies for overcoming drug resistance. The application of these compounds in clinical pract -Abstract Truncated-

KRAS G12D Mutation Predicts Lower TMB and Drives Immune Suppression in Lung Adenocarcinoma.

KRAS Mutation Subtypes Responded Differently to Combination Immunotherapy Via Disturbing Myeloid-Derived Suppressor Cells in Non-Small Cell Lung Cancer.

Evaluating distinct KRAS subtypes as potential biomarkers for immune checkpoint inhibitor efficacy in lung adenocarcinoma

Clinicopathologic features, concurrent genomic alterations, and clinical outcomes of patients with KRAS G12D mutations in resected lung adenocarcinoma

MA15.10 Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma

KRAS-G12D mutation drives immune suppression and the primary resistance of anti-PD-1/PD-L1 immunotherapy in non-small cell lung cancer

Prognostic value of KRAS G12C mutation in lung adenocarcinoma stratified by stages and radiological features

Abstract 2487: KRAS and TP53 co-mutation predicts benefit of immune checkpoint blockade in lung adenocarcinoma

JCSE01.23 Specific TP53 Mutation Subtypes As Biomarker for Response to PD-1/L1 Blockade Immunotherapy in NSCLC

Mutations in KRAS Codon 12 Predict Poor Survival in Chinese Patients with Metastatic Colorectal Cancer.

Dissecting the Clinical Characteristics and Treatment Outcomes Correlates of KRAS G12C-Mutated Non-Small Cell Lung Cancer

Effects of different KRAS mutants and Ki67 expression on diagnosis and prognosis in lung adenocarcinoma

Effects of KRAS, STK11, KEAP1, and TP53 mutations on the clinical outcomes of immune checkpoint inhibitors among patients with lung adenocarcinoma

The Relationship Between Different Subtypes of KRAS and PD-L1 & Tumor Mutation Burden (TMB) Based on Next-Generation Sequencing (NGS) Detection in Chinese Lung Cancer Patients

Abstract A032: KRAS mutations have distinct effects on the tumor immune microenvironment in pancreatic cancer

A Potential Biomarker of Combination of Tumor Mutation Burden and Copy Number Alteration for Efficacy of Immunotherapy in KRAS-Mutant Advanced Lung Adenocarcinoma

A Potential Biomarker of Combination of Tumor Mutation Burden and Copy Number Alteration for Efficacy of Immunotherapy in<i>KRAS</i>-Mutant Advanced Lung Adenocarcinoma

KRAS G12V mutation upregulates PD‐L1 expression via TGF‐β/EMT signaling pathway in human non‐small‐cell lung cancer

Assessing the significance of KRAS G12C mutation: Clinicopathologic features, treatments, and survival outcomes in a real-world KRAS mutant non-small cell lung cancer cohort.

Tumor immune microenvironment of KRAS G12C mutated pancreatic cancer as compared to other mutations and non-cancer pancreata.

Abstract PR012: KRAS mutation-specific effects on the tumor immune microenvironment drive tumor progression in pancreatic cancer